Trevi Therapeutics, Inc. Current Liabilities
Trevi Therapeutics, Inc. (TRVI) had Current Liabilities of $8.74 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $8.74M.
- 2026-03-31: Liabilities, Current $7.12M.
- 2025-12-31: Liabilities, Current $9.75M.
- 2025-09-30: Liabilities, Current $9.04M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $8.74M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.12M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $9.75M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $9.04M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $9.24M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $6.87M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $10.51M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.12M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $6.75M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.28M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $5.82M 10-K · filed 2025-03-18 |
| 2023-09-30 | $5.17M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.71M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $13.20M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $13.40M 10-K · filed 2024-03-20 |
| 2022-09-30 | $14.64M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $15.43M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $12.87M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $12.72M 10-K · filed 2023-03-16 |
| 2021-09-30 | $9.91M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $9.41M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $5.34M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $5.55M 10-K · filed 2022-03-17 |
| 2020-09-30 | $6.10M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $6.77M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $7.21M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $5.20M 10-K · filed 2021-03-25 |
| 2019-09-30 | $5.03M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $7.11M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $3.67M 10-Q · filed 2019-06-14 |
| 2018-12-31 | $2.68M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |